Summary statistics and pathway probabilities for all patients (n=15 684) (Transarterial chemoembolisation (TACE))
Palliative pathways | N | Percentage | Median cost 2 years post-diagnosis |
Unknown cirrhosis status/non-cirrhotic (n=6668) | £6986 | ||
Cytotoxic chemotherapy and other | 137 | 0.9% | £15 011 |
Radiotherapy and other | 100 | 0.6% | £8997 |
Sorafenib and other | 399 | 2.5% | £21 835 |
TACE and other | 999 | 6.4% | £18 863 |
TACE and cytotoxic chemotherapy and other | 55 | 0.4% | £20 708 |
No active treatment | 4978 | 31.7% | £2999 |
Compensated cirrhotic (n=2877) | £11 295 | ||
Cytotoxic chemotherapy and other | 90 | 0.6% | £18 376 |
Other palliative and other | 71 | 0.5% | £13 237 |
Sorafenib and other | 167 | 1.1% | £21 564 |
TACE and other | 909 | 5.8% | £20 690 |
No active treatment | 1643 | 10.5% | £4585 |
Decompensated cirrhotic (n=3008) | £6547 | ||
Other palliative and other | 60 | 0.4% | £16 710 |
Sorafenib and other | 68 | 0.4% | £22 858 |
TACE and other | 285 | 1.8% | £22 476 |
No active treatment | 2595 | 16.5% | £4135 |
Potentially curative pathways | N | Percentage | Median cost 2 years post-diagnosis |
Unknown cirrhosis status/non cirrhotic (n=1336) | £17 371 | ||
Ablation and curative | 268 | 1.7% | £13 674 |
Ablation and palliative | 49 | 0.3% | £24 259 |
Initial palliative and curative | 179 | 1.1% | £26 802 |
Liver resection/transplant and curative | 741 | 4.7% | £14 691 |
Liver resection/transplant and palliative | 99 | 0.6% | £26 973 |
Compensated cirrhotic (n=1218) | £27 279 | ||
Ablation and curative | 449 | 2.9% | £15 484 |
Ablation and palliative | 97 | 0.6% | £24 169 |
Initial palliative and curative | 286 | 1.8% | £44 953 |
Liver resection and other | 269 | 1.7% | £15 815 |
Liver transplant and other | 117 | 0.7% | £58 273 |
Decompensated cirrhotic (n=574) | £29 170 | ||
Ablation and other | 215 | 1.4% | £20 402 |
Initial palliative and curative | 80 | 0.5% | £56 098 |
Liver resection and other | 50 | 0.3% | £14 495 |
Liver transplant and other | 229 | 1.5% | £56 264 |